Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care
Dexcom (NASDAQ: DXCM) unveiled groundbreaking developments at ATTD 2025, including first-ever data for its G7 15 Day system showing an impressive 8.0% MARD, making it the most accurate CGM sensor available. The company also released a multi-region report surveying over 2,500 people across Europe and the Middle East.
Key findings from the report reveal that 52% of healthcare professionals favor CGM technology and education over medication for Type 2 diabetes management. The study showed 93% of CGM users reported positive impact, significantly exceeding pre-use expectations of 77%. Additionally, 96% of HCPs agreed CGM should be standard care for multiple daily insulin injection users.
Dexcom strengthened its position as the most connected CGM brand by announcing new integrations with Omnipod® 5 Automated Insulin Delivery System in multiple regions and direct connectivity with NovoPen® 6 and NovoPen Echo® Plus in Germany, with planned expansion to other markets.
Dexcom (NASDAQ: DXCM) ha presentato sviluppi innovativi al ATTD 2025, inclusi i dati inediti per il suo G7 15 Day system che mostrano un impressionante 8,0% di MARD, rendendolo il sensore CGM più preciso disponibile. L'azienda ha anche rilasciato un rapporto multi-regionale che ha intervistato oltre 2.500 persone in Europa e Medio Oriente.
I risultati chiave del rapporto rivelano che il 52% dei professionisti sanitari preferisce la tecnologia CGM e l'educazione rispetto ai farmaci per la gestione del diabete di tipo 2. Lo studio ha mostrato che il 93% degli utenti di CGM ha riportato un impatto positivo, superando significativamente le aspettative pre-utilizzo del 77%. Inoltre, il 96% dei professionisti sanitari ha concordato sul fatto che la CGM dovrebbe essere la cura standard per gli utenti di insulina a iniezione multipla quotidiana.
Dexcom ha rafforzato la sua posizione come il marchio CGM più connesso annunciando nuove integrazioni con il sistema di somministrazione automatica di insulina Omnipod® 5 in diverse regioni e connettività diretta con NovoPen® 6 e NovoPen Echo® Plus in Germania, con un'espansione pianificata in altri mercati.
Dexcom (NASDAQ: DXCM) presentó desarrollos innovadores en el ATTD 2025, incluidos los primeros datos de su G7 15 Day system, que muestran un impresionante 8.0% de MARD, convirtiéndolo en el sensor CGM más preciso disponible. La empresa también lanzó un informe multirregional encuestando a más de 2.500 personas en Europa y el Medio Oriente.
Los hallazgos clave del informe revelan que el 52% de los profesionales de la salud prefieren la tecnología CGM y la educación por encima de la medicación para el manejo de la diabetes tipo 2. El estudio mostró que el 93% de los usuarios de CGM informaron un impacto positivo, superando significativamente las expectativas previas al uso del 77%. Además, el 96% de los profesionales de la salud coincidieron en que la CGM debería ser el estándar de atención para los usuarios de inyección de insulina múltiple diaria.
Dexcom fortaleció su posición como la marca CGM más conectada al anunciar nuevas integraciones con el sistema de entrega de insulina automatizado Omnipod® 5 en múltiples regiones y conectividad directa con NovoPen® 6 y NovoPen Echo® Plus en Alemania, con planes de expansión a otros mercados.
Dexcom (NASDAQ: DXCM)는 ATTD 2025에서 혁신적인 발전을 발표했습니다. 여기에는 G7 15 Day system에 대한 최초의 데이터가 포함되어 있으며, 8.0%의 MARD를 기록하여 가장 정확한 CGM 센서로 자리 잡았습니다. 이 회사는 또한 유럽과 중동 전역에서 2,500명 이상을 대상으로 한 다지역 보고서를 발표했습니다.
보고서의 주요 결과는 52%의 의료 전문가가 제2형 당뇨병 관리를 위해 약물보다 CGM 기술과 교육을 선호한다는 것을 보여줍니다. 연구에 따르면 CGM 사용자 중 93%가 긍정적인 영향을 보고했으며, 이는 사용 전 기대치인 77%를 크게 초과한 수치입니다. 또한, 96%의 의료 전문가는 CGM이 여러 번의 인슐린 주사를 사용하는 환자에게 표준 치료가 되어야 한다고 동의했습니다.
Dexcom은 여러 지역에서 Omnipod® 5 자동 인슐린 전달 시스템과의 새로운 통합을 발표하고 독일에서 NovoPen® 6 및 NovoPen Echo® Plus와의 직접 연결을 통해 가장 연결된 CGM 브랜드로서의 입지를 강화했습니다. 다른 시장으로의 확장도 계획하고 있습니다.
Dexcom (NASDAQ: DXCM) a dévoilé des développements révolutionnaires lors de l'ATTD 2025, y compris les premières données de son G7 15 Day system, affichant un impressionnant 8,0 % de MARD, ce qui en fait le capteur CGM le plus précis disponible. L'entreprise a également publié un rapport multi-régional enquêtant plus de 2 500 personnes à travers l'Europe et le Moyen-Orient.
Les principales conclusions du rapport révèlent que 52 % des professionnels de santé préfèrent la technologie CGM et l'éducation plutôt que les médicaments pour la gestion du diabète de type 2. L'étude a montré que 93 % des utilisateurs de CGM ont rapporté un impact positif, dépassant de manière significative les attentes avant utilisation de 77 %. De plus, 96 % des professionnels de santé ont convenu que la CGM devrait être le soin standard pour les utilisateurs d'injections d'insuline multiples quotidiennes.
Dexcom a renforcé sa position en tant que marque CGM la plus connectée en annonçant de nouvelles intégrations avec le système de délivrance d'insuline automatisé Omnipod® 5 dans plusieurs régions et une connectivité directe avec NovoPen® 6 et NovoPen Echo® Plus en Allemagne, avec une expansion prévue vers d'autres marchés.
Dexcom (NASDAQ: DXCM) stellte auf der ATTD 2025 bahnbrechende Entwicklungen vor, darunter die ersten Daten für sein G7 15 Day system, das einen beeindruckenden MARD von 8,0 % aufweist und somit der genaueste verfügbare CGM-Sensor ist. Das Unternehmen veröffentlichte auch einen mehrregionalen Bericht, der über 2.500 Personen in Europa und dem Nahen Osten befragte.
Wesentliche Erkenntnisse aus dem Bericht zeigen, dass 52 % der Gesundheitsfachkräfte die CGM-Technologie und -Schulung der Medikation zur Behandlung von Typ-2-Diabetes vorziehen. Die Studie ergab, dass 93 % der CGM-Nutzer einen positiven Einfluss berichteten, was die Erwartungen vor der Nutzung von 77 % erheblich überstieg. Darüber hinaus stimmten 96 % der Gesundheitsfachkräfte zu, dass CGM die Standardversorgung für Nutzer von mehrfachen täglichen Insulininjektionen sein sollte.
Dexcom stärkte seine Position als die am besten vernetzte CGM-Marke, indem es neue Integrationen mit dem Omnipod® 5 automatisierten Insulinabgabesystem in mehreren Regionen und eine direkte Verbindung zu NovoPen® 6 und NovoPen Echo® Plus in Deutschland ankündigte, mit einer geplanten Expansion in andere Märkte.
- Most accurate CGM sensor with 8.0% MARD for G7 15 Day system
- 93% positive impact reported by CGM users, exceeding pre-use expectations
- Expansion of device integration partnerships across multiple regions
- Strong HCP support with 96% recommending CGM for insulin users
- Significant barriers to adoption including funding constraints (35%)
- market availability with G7 15 Day still pending FDA approval
- Narrow inclusion criteria limiting wider adoption (20%)
Insights
Dexcom's new G7 15 Day system represents a significant product advancement with its industry-leading 8.0% MARD (mean absolute relative difference) - a key technical metric where lower numbers indicate superior accuracy in continuous glucose monitoring. This positions Dexcom as having potentially the most accurate CGM sensor on the market, a critical competitive differentiator in the diabetes technology space.
The announcement of expanded integrations with Omnipod 5 Automated Insulin Delivery System across multiple international markets (Australia, Netherlands, with Belgium, Canada and Switzerland launching soon) strengthens Dexcom's ecosystem strategy. The new NovoPen integrations in Germany further cement Dexcom's claim as the most connected CGM brand globally, creating valuable network effects and potential customer stickiness.
Most strategically significant is the company's deliberate focus on the Type 2 diabetes market, which represents 90-95% of the 134 million people with diabetes across Europe, Middle East and North Africa. The multi-region survey provides Dexcom with evidence-based ammunition for policymakers to expand CGM reimbursement beyond traditional Type 1 patients. With HCPs increasingly viewing CGM as standard care (96% for MDI users, 86% for basal insulin users), Dexcom is positioning for substantial market expansion if reimbursement barriers can be overcome.
The company's dual approach - developing advanced technology while simultaneously building market access through targeted research - demonstrates a sophisticated strategy to drive both product superiority and expanded market access.
The 8.0% MARD achievement for Dexcom's G7 15 Day system is technically impressive, placing it at the forefront of glucose monitoring accuracy. For context, lower MARD values directly correlate with clinical reliability - every percentage point improvement meaningfully reduces the gap between CGM readings and actual blood glucose values, potentially enabling more precise insulin dosing decisions.
The extended 15-day wear period (versus the standard 10 days) offers both patient convenience and economic advantages. Fewer sensor changes translate to reduced per-patient costs, a critical factor for expanding insurance coverage. The system's FDA review status indicates commercialization could be relatively near-term.
Dexcom's integration strategy is technically sophisticated. The Omnipod 5 integration creates a hybrid closed-loop system that automates insulin adjustments, while the NovoPen smart insulin pen integration addresses the larger market of non-pump users. The unique Follow app connectivity during Omnipod use represents a technical differentiation that competitors currently can't match.
The company's research strategically targets reimbursement expansion by documenting healthcare professional preference for CGM technology (52%) over new medications (38%) for Type 2 management. This aligns with evolving diabetes care paradigms that emphasize real-time data feedback over pharmaceutical interventions alone. The 93% satisfaction rate among Type 2 CGM users versus 77% expectation among non-users demonstrates the technology's clinical value proposition extends successfully beyond the traditional Type 1 market.
-
At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of
8.0% , making it the most accurate CGM sensor.2 - New Dexcom G7 automated insulin delivery and smart insulin pen integrations also announced at ATTD reinforce the company’s status as the most connected CGM brand in the world.3
During the conference, first-ever accuracy and performance data for Dexcom G7 15 Day,1 will be presented, showcasing an overall mean absolute relative difference (MARD) of
Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the
With a foreword from the International Diabetes Federation Europe, and recommendations for improving access to education and diabetes technology throughout, the Dexcom State of Type 2 report serves as a call to action for policymakers. It highlights the benefits of CGM technology for the 134 million4,5 people living with diabetes across
-
Tech, not medication, is the future of T2 care:
52% of HCPs ranked access to CGM and education as having the potential to positively help people with Type 2 manage their condition in the next 10 years, compared with38% who cited better or more effective medications.8 -
Reality exceeds expectation with CGM use:
77% of people with Type 2 diabetes who had not used CGM expected it to improve the lives of those with Type 2 compared to93% of people with Type 2 diabetes who had used CGM and agreed it had a positive impact.8 -
HCPs see CGM as the ‘standard of care’: Half of all HCPs felt CGM should be the standard of care for people with Type 2 diabetes whether they were using insulin to manage the condition or not.
96% of HCPs agreed those using multiple daily injections of insulin should receive CGM and86% agreed those relying on basal insulin should be offered CGM.8 -
Barriers to CGM adoption and the case for improved access: HCPs see funding constraints (
35% ) and narrow inclusion criteria (20% ) as the primary barriers to CGM adoption.22% of HCPs believe increasing education for people with Type 2 diabetes could drive higher CGM usage.8
“With policymakers increasingly focused on digital transformation in healthcare, now is the time to push for greater investment in CGM technology as a core component of Type 2 management,” said Adrian Gut, senior director of international access, advocacy and value at Dexcom. “Enhancing CGM accessibility is crucial to tackling the Type 2 crisis. By ensuring equitable access to this life-changing technology, we can empower people with Type 2 to take control of their diabetes management, improve their quality of life and reduce complications. This will significantly improve public health outcomes and reduce long-term healthcare costs. Now is the time to make a transformative impact on the lives of millions.”
Read the full Dexcom State of Type 2 report at https://bit.ly/DexcomATTD2025
Data demonstrates Dexcom G7 15 Day1 is the only CGM system with a MARD accuracy as low as
In a variety of symposia and presentations at ATTD this year, clinical evidence will continue to demonstrate the impact and value of Dexcom CGM among people with all types of diabetes. Of note, data evaluating the accuracy of its new Dexcom G7 15 Day sensor1 will be presented on March 20 at 1 p.m. CET in Hall D. With a MARD of
Dexcom CGM builds on “most connected CGM brand” with new integrations announced at ATTD
Dexcom is strengthening its position as the most connected CGM brand in the world3 by integrating Dexcom G7 with the Omnipod® 5 Automated Insulin Delivery System. Following availability in the US in 2024, Dexcom G7 is now available with Omnipod® 5 in
Dexcom G7 now also directly connects with NovoPen® 6 and NovoPen Echo® Plus in
For more information about Dexcom presentations at ATTD and to register to virtually attend the conference, visit https://attd.kenes.com/. To read the Dexcom State of Type 2 Report, visit https://bit.ly/DexcomATTD2025.
About DexCom, Inc.
Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.
Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.
Category: IR
To learn more about insulin pump integration and compatibility with Dexcom CGM systems, visit Dexcom.com/integrate. Smart devices sold separately. For a list of compatible devices, visit Dexcom.com/compatibility.
1 Dexcom G7 15 Day is 510(k) pending. Not available for sale or distribution in
† Users should always confirm readings and trend on the Dexcom G7 app or receiver before making treatment decisions.
* Separate Dexcom Follow app and internet connection required.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319951823/en/
Media Contact
Gemma McDonald
+44 7552 368398
mediarelations@dexcom.com
Investor Contact
Sean Christensen
+1 858 203 6657
sean.christensen@dexcom.com
Source: DexCom, Inc.
FAQ
What accuracy rate did Dexcom's new G7 15 Day system achieve in 2025?
How many healthcare professionals prefer CGM technology over medication for Type 2 diabetes management according to Dexcom's 2025 report?
What percentage of Type 2 diabetes patients reported positive impact after using Dexcom CGM?
What are the main barriers to CGM adoption according to Dexcom's 2025 report?
Which new integration partnerships did DXCM announce at ATTD 2025?
